Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Patients with treatment-requiring chronic lymphocytic leukemia (CLL)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Life expectancy \>6 months~Exclusion Criteria:~* Transformation to aggressive B-cell malignancy~* History of other malignancy unless the patient was treated with curative intent and has been in remission for more than 5 years prior to enrolment~* HIV or Hepatitis B positive unless clearly due to vaccination~* Inadequate liver or renal function~* Any coexisting medical or psychological condition that would preclude participation in the required study procedures~Additional exclusion criterion for Part 1:~* Any previous treatment for CLL except for up to 4 cycles of rituximab IV in combination with FC chemotherapy as first-line treatment for CLL~Additional exclusion criterion for Part 2:~* Any previous treatment for CLL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).